Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

13. Oktober 2025 08:45 ET | Quelle: Palisade Bio, Inc.

Palisade Bio Granted Canadian Patent Covering Composition of Lead Product Candidate PALI-2108

PALI-2108 is the first and only PDE4 inhibitor designed to target terminal ileum and colon for fibrostenotic Crohn’s disease (FSCD) and ulcerative colitis (UC) to address significant unmet medical...
16. April 2024 08:30 ET | Quelle: Palisade Bio, Inc.

Palisade Bio Successfully Demonstrates Bioactivation of PALI-2108 In Ex-Vivo Study of Normal Healthy and Ulcerative Colitis Patients’ Stool

Company continues advancing ongoing development of targeted therapies for ulcerative colitis (UC) Carlsbad, CA, April 16, 2024 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI)...
15. Februar 2024 08:35 ET | Quelle: Palisade Bio, Inc.

Palisade Bio to Present at Digestive Disease Week (DDW) 2024

Carlsbad, CA, Feb. 15, 2024 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade” or the “Company”), a biopharmaceutical company focused on developing novel therapeutics for serious...
07. Januar 2020 12:30 ET | Quelle: Franciosi Consulting Ltd.

Luigi Franciosi to Advise on New Asthma & COPD Drug Development Programs for Vicenna Pharmaceuticals Inc.

VANCOUVER, British Columbia, Jan. 07, 2020 (GLOBE NEWSWIRE) -- Franciosi Consulting Ltd. (“FCL”) is pleased to announce that its President and CEO, Dr. Luigi Franciosi, has been retained as a...